For Immediate Release

Chicago, IL – August 25, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: News Corp. (NWS), McGraw-Hill (MHP), NYSE Euronext (NYX), Thomson Reuters (TRIN) and Novartis (NVS).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday’s Analyst Blog:

Dow Jones to Change Hands

Dow Jones & Co., owned by News Corp. (NWS), has started seeking potential buyers for its stock market index business, including the renowned benchmark Dow Jones Industrial Average.

Goldman Sachs has been appointed to explore strategic options for the business. News Corp. bought

...

Willdan Group, Inc. (”Willdan”) (NASDAQ: WLDN) August 25, 2009 announced that its wholly-owned subsidiary, Willdan Energy Solutions (WES), was awarded a $67 million contract with Consolidated Edison Company of New York, Inc., (Con Edison), a subsidiary of Consolidated Edison, Inc. (NYSE: ED), to implement Con Edison’s new energy efficiency program for small business customers.

Novartis (NYSE: NVS) aAugust 25, 2009 announced that it has received approval from the European Commission (EC) for the use of Xolair (omalizumab) as an add-on therapy for severe persistent allergic asthma in children in the age group of 6 to 11 years.

Yahoo! Inc. (Nasdaq:YHOO) August 25, 2009 announced it has entered into a definitive agreement to acquire Maktoob.com, the leading online community in the Arab world, with more than 16.5 million unique users.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or

...

This morning, Novartis (NVS) announced that it has received approval from the European Commission (EC) for the use of Xolair (omalizumab) as an add-on therapy for severe persistent allergic asthma in children in the age group of 6 to 11 years. The approval is positive news for the company and should expand the patient base for the drug. Asthma is a chronic lung disease which is estimated to affect about 10% of children in Europe. It is also the most common cause of school absenteeism and children often use oral corticosteroids to deal with the disease. However, despite conventional therapy, severe asthma remains uncontrolled in more than 50% of children with this condition. Xolair is a humanized monoclonal antibody aimed at treating the underlying mechanism of allergic asthma. The product works by blocking the action of immunoglobulin E (IgE). This helps in preventing the onset of ...